<DOC>
	<DOC>NCT01670435</DOC>
	<brief_summary>This study is a post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Ciproxan intravenously as a first-line treatment for sepsis, secondary skin infections followed by superficial burn, post-surgical or post-traumatic, pneumonia, peritonitis, cholecystitis, cholangitis, anthrax. The objective of this study is to assess safety and efficacy of Ciproxan in daily clinical practice. A total of 3,000 patients are to be enrolled and assessed during the period of treatment with Ciproxan.</brief_summary>
	<brief_title>Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Patients who received Ciproxan as a firstline treatment were eligible for the study, among those with sepsis, secondary infection due to trauma, burn, or surgical wound, pneumonia, peritonitis, cholecystitis, cholangitis, and anthrax as the indications of this drug. Patients who are contraindicated based on the product label.</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Ciprofloxacin</keyword>
	<keyword>sepsis</keyword>
	<keyword>infection</keyword>
	<keyword>pneumonia</keyword>
	<keyword>peritonitis</keyword>
	<keyword>cholecystitis</keyword>
	<keyword>cholangitis</keyword>
	<keyword>anthrax</keyword>
</DOC>